| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 3,860,082 | 5,570,730 | ||
| Interest receivable | 12,791 | 19,039 | ||
| Prepaid expenses and other current assets | 116,015 | 358,357 | ||
| Deferred offering costs | 90,838 | 23,861 | ||
| Total current assets | 4,079,726 | 5,971,987 | ||
| Property, plant and equipment, net | 5,729 | 4,277 | ||
| Other assets | 2,167 | 2,167 | ||
| Total assets | 4,087,622 | 5,978,431 | ||
| Accounts payable | 614,127 | 895,609 | ||
| Accrued liabilities | 738,548 | 783,909 | ||
| Total current liabilities | 1,352,675 | 1,679,518 | ||
| Total liabilities | 1,352,675 | 1,679,518 | ||
| Common stock, 0.001 par value 75,000,000 shares authorized, 2,059,754 shares issued and outstanding as of september 30, 2025 1,782,486 shares issued and outstanding as of december 31, 2024 | 2,059 | 2,006 | ||
| Additional paid-in capital | 38,654,043 | 37,532,357 | ||
| Accumulated deficit | -35,921,155 | -33,235,450 | ||
| Total stockholders equity | 2,734,947 | 4,298,913 | ||
| Total liabilities and stockholders equity | 4,087,622 | 5,978,431 | ||
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)